Novo Nordisk invests $2.4B in French facility to address booming GLP-1 demandnews2023-11-27T11:54:39+00:00November 27th, 2023|Endpoints News|
GSK says multiple myeloma drug Blenrep extended progression-free survival in PhIIInews2023-11-27T07:00:53+00:00November 27th, 2023|Endpoints News|
Sanofi, Regeneron say Dupixent succeeds in another late-stage COPD study, setting up filing for FDA approvalnews2023-11-27T06:30:37+00:00November 27th, 2023|Endpoints News|
Merck’s neuro-inspired buyout; Bayer’s bad week; One launch, one shutdown for Flagship; and morenews2023-11-25T11:00:53+00:00November 25th, 2023|Endpoints News|
FDA warns Genentech clinical investigator working on preventive flu antiviral trialnews2023-11-22T19:20:05+00:00November 22nd, 2023|Endpoints News|
AbbVie sues five generic companies over potential Rinvoq competitorsnews2023-11-22T18:47:45+00:00November 22nd, 2023|Endpoints News|
Recipharm to change CEOs, spin out inhaler businessnews2023-11-22T18:40:31+00:00November 22nd, 2023|Endpoints News|
US International Trade Commission takes on Eli Lilly’s tirzepatide casenews2023-11-22T18:12:30+00:00November 22nd, 2023|Endpoints News|
Boehringer Ingelheim acquires immunotherapy biotech T3 Pharmaceuticals for $507Mnews2023-11-22T17:32:46+00:00November 22nd, 2023|Endpoints News|
Bayer’s turnaround plan: Focus on specialty drugs, lower costs and fewer big betsnews2023-11-22T16:35:08+00:00November 22nd, 2023|Endpoints News|
